Rezolute, Inc. Common Stock (NV) (RZLT) Stock Price

RZLTStock
$4.6236.01%52W
Market Cap$444.87M
P/E
PEG Ratio
Div yield
Beta0.49

RZLT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)16.05%
Price vs S&P 500 (4W)-7.45%
VGM Score54.39

RZLT Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q4 2025-$0.18-$0.22-22.22%(-$0.04)
Q3 2025-$0.26-$0.18+31.21%(+$0.08)
Q2 2025-$0.23-$0.26-10.64%(-$0.03)

RZLT Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.13
4.19
4.19

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
RZLTRezolute, Inc. Common Stock (NV)
C$4.62
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Rezolute, Inc. Common Stock (NV)

Rezolute is a clinical-stage biopharmaceutical company developing therapies for rare metabolic diseases, including congenital hyperinsulinism, a rare endocrine disorder characterized by excessive insulin production and hypoglycemia. Its pipeline candidates aim to improve patient outcomes with reduced treatment burdens. Value creation depends on successful clinical development and regulatory approval.